{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:13:09Z","timestamp":1774275189164,"version":"3.50.1"},"reference-count":96,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: This retrospective cohort study aimed to explore the association between short-term genitourinary (GU) and gastrointestinal (GI) toxicity and oncological outcomes in high-risk prostate cancer patients treated with external beam radiotherapy (EBRT) alone or with high-dose-rate brachytherapy (HDR-BT).Patient\/material and methods: High-risk prostate cancer patients treated at \u00d6rebro University Hospital (2008\u20132021) were divided into two cohorts based on treatment modality: EBRT-only (66 Gy\/22 fractions), EBRT-BT (42 Gy\/14 fractions + 14.5 Gy HDR-BT-boost).Maximum 6-month toxicity grade was categorised as: GU-low (grade 0\u20131), GU-high (grade \u2265 2), GI-low (grade 0) and GI-high (grade \u2265 1), respectively. Freedom from biochemical failure (FFBF), metastasis-free survival (MFS) and overall survival were compared between the low- and high- toxicity groups, using Kaplan\u2013Meier and Cox proportional hazards regression. Prostate cancer-specific mortality was compared between the groups using the Aalen\u2013Johansen method and Fine-Gray regression.Results: The EBRT-only cohort encompassed 114 and 162 patients for GU- and GI-analyses. The EBRT-BT cohort comprised 306 patients for GU- and 344 patients for GI-analyses. High GU-toxicity was associated with inferior FFBF (adjusted hazard ratio (aHR) = 2.57, 95% Confidence Interval [CI] = 1.32\u20135.00) and MFS (aHR = 2.22, 95% CI = 1.21\u20134.07) in the EBRT-only but not in the EBRT-BT cohort. No statistically significant associations were found between GI-toxicity and oncological outcomes.Interpretation: Early grade \u2265 2 GU-toxicity was linked to worse FFBR and MFS after EBRT alone, whereas no such association was seen after EBRT-BT. GI toxicity showed no prognostic impact. These exploratory findings warrant validation in larger studies addressing interactions between patient-, tumour- and treatment-related factors.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45030","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:38:57Z","timestamp":1774273137000},"page":"241-251","source":"Crossref","is-referenced-by-count":0,"title":["Association between short-term radiation-induced toxicity and oncological outcomes in high-risk prostate cancer: a retrospective single-centre cohort study"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9272-9479","authenticated-orcid":false,"given":"Jenny","family":"Kahlmeter Brandell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0194","authenticated-orcid":false,"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-5300","authenticated-orcid":false,"given":"Henrik","family":"Ugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-8041","authenticated-orcid":false,"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7007-4054","authenticated-orcid":false,"given":"Bengt","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"145987","unstructured":"National Comprehensive Cancer Network. Prostate cancer (Version 1.2025) [Internet]. [Cited date: 19-05-2025]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"145988","unstructured":"EAU guidelines [Internet]. Arnhem: EAU Guidelines Office; 2024 [Edn. presented at the EAU Annual Congress Paris]. [Cited date: 18-07-2024]. Available from: https:\/\/uroweb.org\/eau-guidelines"},{"key":"145989","doi-asserted-by":"crossref","unstructured":"David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, et al. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26(1):8\u201315.","DOI":"10.1038\/s41391-022-00520-x"},{"key":"145990","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41391-022-00520-x","DOI":"10.1038\/s41391-022-00520-x"},{"key":"145991","doi-asserted-by":"crossref","unstructured":"S\u00e6len MG, Hjelle LV, Aars\u00e6ther E, Knutsen T, Andersen S, Bentzen AG, et al. Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy. Acta Oncol. 2023;62(6):657\u201365.","DOI":"10.1080\/0284186X.2023.2224051"},{"key":"145992","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186x.2023.2224051","DOI":"10.1080\/0284186X.2023.2224051"},{"key":"145993","doi-asserted-by":"crossref","unstructured":"Nikitas J, Jamshidian P, Tree AC, Hall E, Dearnaley D, Michalski JM, et al. The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol. 2025;26(3):378\u201386.","DOI":"10.1016\/S1470-2045(24)00720-4"},{"key":"145994","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(24)00720-4","DOI":"10.1016\/S1470-2045(24)00720-4"},{"key":"145995","doi-asserted-by":"crossref","unstructured":"Spampinato S, Rancati T, Waskiewicz JM, Avuzzi B, Garibaldi E, Faiella A, et al. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors. Acta Oncol. 2023;62(11):1440\u201350.","DOI":"10.1080\/0284186X.2023.2259597"},{"key":"145996","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186x.2023.2259597","DOI":"10.1080\/0284186X.2023.2259597"},{"key":"145997","doi-asserted-by":"crossref","unstructured":"Nasser NJ, Klein J, Agbarya A. Markers of toxicity and response to radiation therapy in patients with prostate cancer. Adv Radiat Oncol. 2021;6(1):100603.","DOI":"10.1016\/j.adro.2020.10.016"},{"key":"145998","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.adro.2020.10.016","DOI":"10.1016\/j.adro.2020.10.016"},{"key":"145999","unstructured":"Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A,"},{"key":"146000","doi-asserted-by":"crossref","unstructured":"et al. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):608\u201316.","DOI":"10.1016\/j.ijrobp.2011.07.019"},{"key":"146001","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.07.019","DOI":"10.1016\/j.ijrobp.2011.07.019"},{"key":"146002","unstructured":"Roy S, Spratt DE, Morgan SC, Zhou M, D\u2019Souza LA, Drogos F,"},{"key":"146003","doi-asserted-by":"crossref","unstructured":"et al. Association of short-term patient-reported outcomes with long-term oncologic outcomes in localized prostate cancer patients treated with radiation therapy and androgen deprivation therapy in a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2022;112(4):880\u20139.","DOI":"10.1016\/j.ijrobp.2021.11.010"},{"key":"146004","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.11.010","DOI":"10.1016\/j.ijrobp.2021.11.010"},{"key":"146005","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244\u201352.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"146006","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/pas.0000000000000530","DOI":"10.1097\/PAS.0000000000000530"},{"key":"146007","doi-asserted-by":"crossref","unstructured":"Kahlmeter Brandell J, Valachis A, Ugge H, Smith D, Johansson B. Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: a retrospective real-world single-center cohort study. Clin Transl Radiat Oncol. 2024;48:100846.","DOI":"10.1016\/j.ctro.2024.100846"},{"key":"146008","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100846","DOI":"10.1016\/j.ctro.2024.100846"},{"key":"146009","doi-asserted-by":"crossref","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3\u20139.","DOI":"10.1016\/j.ijrobp.2009.09.040"},{"key":"146010","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.040","DOI":"10.1016\/j.ijrobp.2009.09.040"},{"key":"146011","unstructured":"Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C,"},{"key":"146012","doi-asserted-by":"crossref","unstructured":"et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75(1):29\u201335.","DOI":"10.1016\/j.ijrobp.2008.10.086"},{"key":"146013","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.086","DOI":"10.1016\/j.ijrobp.2008.10.086"},{"key":"146014","doi-asserted-by":"crossref","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395.","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"146015","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s0140-6736(19)31131-6","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"146016","doi-asserted-by":"crossref","unstructured":"Karlsson L, Thunberg P, Johansson B, Persliden J. The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer. J Contemp Brachytherapy. 2014;6(3):282\u20138.","DOI":"10.5114\/jcb.2014.45586"},{"key":"146017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5114\/jcb.2014.45586","DOI":"10.5114\/jcb.2014.45586"},{"key":"146018","doi-asserted-by":"crossref","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136.","DOI":"10.1016\/0360-3016(95)00060-C"},{"key":"146019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0360-3016(95)00060-c","DOI":"10.1016\/0360-3016(95)00060-C"},{"key":"146020","doi-asserted-by":"crossref","unstructured":"Roach M, 3rd, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965\u201374.","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"146021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"146022","doi-asserted-by":"crossref","unstructured":"Woo S, Han S, Kim TH, Suh CH, Westphalen AC, Hricak H, et al. Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: a systematic review and meta-analysis. AJR Am J Roentgenol. 2020;214(3):597\u2013604.","DOI":"10.2214\/AJR.19.21836"},{"key":"146023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2214\/ajr.19.21836","DOI":"10.2214\/AJR.19.21836"},{"key":"146024","doi-asserted-by":"crossref","unstructured":"Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686\u201392.","DOI":"10.1016\/j.ijrobp.2012.05.023"},{"key":"146025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2012.05.023","DOI":"10.1016\/j.ijrobp.2012.05.023"},{"key":"146026","unstructured":"Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J,"},{"key":"146027","doi-asserted-by":"crossref","unstructured":"et al. The clinical significance of maximum tumor diameter on MRI in men undergoing radical prostatectomy or definitive radiotherapy for locoregional prostate cancer. Clin Genitourin Cancer. 2022;20(6):e453\u20139.","DOI":"10.1016\/j.clgc.2022.06.010"},{"key":"146028","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.010","DOI":"10.1016\/j.clgc.2022.06.010"},{"key":"146029","unstructured":"Quinn TJ, Chapman D, Parzen J, Wahl DR, McNamara A, Dess R,"},{"key":"146030","doi-asserted-by":"crossref","unstructured":"et al. Validation of the combination Gleason Score as an independent favorable prognostic factor in prostate cancer treated with dose-escalated radiation therapy. Pract Radiat Oncol. 2023;13(2):e166\u201375.","DOI":"10.1016\/j.prro.2022.08.013"},{"key":"146031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.prro.2022.08.013","DOI":"10.1016\/j.prro.2022.08.013"},{"key":"146032","doi-asserted-by":"crossref","unstructured":"Ols\u00e9n JS, Estefan D, Valachis A, Jakobsson F, Karlsson L, Johansson B. Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer. J Contemp Brachytherapy. 2022;14(1):7\u201314.","DOI":"10.5114\/jcb.2022.113545"},{"key":"146033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5114\/jcb.2022.113545","DOI":"10.5114\/jcb.2022.113545"},{"key":"146034","doi-asserted-by":"crossref","unstructured":"Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D\u2019Andrea D, et al. Association of smoking status with recurrence, metastasis, and mortality among patients with localized prostate cancer undergoing prostatectomy or radiotherapy: a systematic review and meta-analysis. JAMA Oncol. 2018;4(7):953\u201361.","DOI":"10.1001\/jamaoncol.2018.1071"},{"key":"146035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1071","DOI":"10.1001\/jamaoncol.2018.1071"},{"key":"146036","doi-asserted-by":"crossref","unstructured":"Bergman M, Fountoukidis G, Smith D, Ahlgren J, Lambe M, Valachis A. Effect of smoking on treatment efficacy and toxicity in patients with cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;14(17):4117.","DOI":"10.3390\/cancers14174117"},{"key":"146037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers14174117","DOI":"10.3390\/cancers14174117"},{"key":"146038","unstructured":"Ghanem AI, Khalil RM, Khedr GA, Tang A, Elsaid AA, Chetty IJ, et al. Charlson comorbidity score influence on prostate cancer survival and radiation-related toxicity. Can J Urol. 2020;27(2):10154\u201361."},{"key":"146039","doi-asserted-by":"crossref","unstructured":"Lehtonen M, Heiskanen L, Reinikainen P, Kellokumpu-Lehtinen PL. Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. BMC Cancer. 2020;20(1):324.","DOI":"10.1186\/s12885-020-06812-6"},{"key":"146040","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-020-06812-6","DOI":"10.1186\/s12885-020-06812-6"},{"key":"146041","doi-asserted-by":"crossref","unstructured":"Roeske JC, Forman JD, Mesina CF, He T, Pelizzari CA, Fontenla E, et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33(5):1321\u20139.","DOI":"10.1016\/0360-3016(95)00225-1"},{"key":"146042","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0360-3016(95)00225-1","DOI":"10.1016\/0360-3016(95)00225-1"},{"key":"146043","doi-asserted-by":"crossref","unstructured":"Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995;37(1):35\u201342.","DOI":"10.1016\/0167-8140(95)01613-L"},{"key":"146044","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0167-8140(95)01613-l","DOI":"10.1016\/0167-8140(95)01613-L"},{"key":"146045","doi-asserted-by":"crossref","unstructured":"Nichol AM, Brock KK, Lockwood GA, Moseley DJ, Rosewall T, Warde PR, et al. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. Int J Radiat Oncol Biol Phys. 2007;67(1):48\u201356.","DOI":"10.1016\/j.ijrobp.2006.08.021"},{"key":"146046","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2006.08.021","DOI":"10.1016\/j.ijrobp.2006.08.021"},{"key":"146047","doi-asserted-by":"crossref","unstructured":"de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(4):965\u201373.","DOI":"10.1016\/j.ijrobp.2004.11.032"},{"key":"146048","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2004.11.032","DOI":"10.1016\/j.ijrobp.2004.11.032"},{"key":"146049","doi-asserted-by":"crossref","unstructured":"Paluska P, Hanus J, Sefrova J, Rouskova L, Grepl J, Jansa J, et al. Utilization of cone beam CT for reconstruction of dose distribution delivered in image-guided radiotherapy of prostate carcinoma \u2013 bony landmark setup compared to fiducial markers setup. J Appl Clin Med Phys. 2013;14(3):4203.","DOI":"10.1120\/jacmp.v14i3.4203"},{"key":"146050","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1120\/jacmp.v14i3.4203","DOI":"10.1120\/jacmp.v14i3.4203"},{"key":"146051","doi-asserted-by":"crossref","unstructured":"O\u2019Neill AG, Jain S, Hounsell AR, O\u2019Sullivan JM. Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. 2016;89(1068):20160296.","DOI":"10.1259\/bjr.20160296"},{"key":"146052","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1259\/bjr.20160296","DOI":"10.1259\/bjr.20160296"},{"key":"146053","doi-asserted-by":"crossref","unstructured":"Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125\u20139.","DOI":"10.1016\/j.ijrobp.2011.11.047"},{"key":"146054","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.11.047","DOI":"10.1016\/j.ijrobp.2011.11.047"},{"key":"146055","doi-asserted-by":"crossref","unstructured":"Ghadjar P, Fiorino C, Munck Af Rosensch\u00f6ld P, Pinkawa M, Zilli T, van der Heide UA. ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol. 2019;141:5\u201313.","DOI":"10.1016\/j.radonc.2019.08.027"},{"key":"146056","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2019.08.027","DOI":"10.1016\/j.radonc.2019.08.027"},{"key":"146057","doi-asserted-by":"crossref","unstructured":"Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys. 1999;43(1):57\u201366.","DOI":"10.1016\/S0360-3016(98)00351-4"},{"key":"146058","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s0360-3016(98)00351-4","DOI":"10.1016\/S0360-3016(98)00351-4"},{"key":"146059","doi-asserted-by":"crossref","unstructured":"Sander L, Langkilde NC, Holmberg M, Carl J. MRI target delineation may reduce long-term toxicity after prostate radiotherapy. Acta Oncol. 2014;53(6):809\u201314.","DOI":"10.3109\/0284186X.2013.865077"},{"key":"146060","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/0284186x.2013.865077","DOI":"10.3109\/0284186X.2013.865077"},{"key":"146061","doi-asserted-by":"crossref","unstructured":"Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol. 2022;23(12):e534\u201343.","DOI":"10.1016\/S1470-2045(22)00544-7"},{"key":"146062","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(22)00544-7","DOI":"10.1016\/S1470-2045(22)00544-7"},{"key":"146063","doi-asserted-by":"crossref","unstructured":"Lyu F, Shang SY, Gao XS, Ma MW, Xie M, Ren XY, et al. Uncovering the secrets of prostate cancer\u2019s radiotherapy resistance: advances in mechanism research. Biomedicines. 2023;11(6):1628.","DOI":"10.3390\/biomedicines11061628"},{"key":"146064","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/biomedicines11061628","DOI":"10.3390\/biomedicines11061628"},{"key":"146065","doi-asserted-by":"crossref","unstructured":"Chen X, Chen F, Ren Y, Weng G, Xu L, Xue X, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1\/2. J Cancer Res Clin Oncol. 2019;145(6):1471\u201384.","DOI":"10.1007\/s00432-019-02917-z"},{"key":"146066","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00432-019-02917-z","DOI":"10.1007\/s00432-019-02917-z"},{"key":"146067","doi-asserted-by":"crossref","unstructured":"Wu C-T, Chen M-F, Chen W-C, Hsieh C-C. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 2013;8(1):159.","DOI":"10.1186\/1748-717X-8-159"},{"key":"146068","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1748-717X-8-159","DOI":"10.1186\/1748-717X-8-159"},{"key":"146069","unstructured":"Lopes CO, Callera F. Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but"},{"key":"146070","unstructured":"not IL-2, IL-4, IL-5, tumor necrosis factor-\u03b1, MIP-1-\u03b1, and LIF levels."},{"key":"146071","doi-asserted-by":"crossref","unstructured":"Int J Radiat Oncol Biol Phys. 2012;82(4):1385\u20138.","DOI":"10.1016\/j.ijrobp.2011.11.079"},{"key":"146072","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.04.040","DOI":"10.1016\/j.ijrobp.2011.04.040"},{"key":"146073","doi-asserted-by":"crossref","unstructured":"Christensen E, Pintilie M, Evans KR, Lenarduzzi M, M\u00e9nard C, Catton CN, et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res. 2009;15(17):","DOI":"10.1158\/1078-0432.CCR-09-0245"},{"key":"146074","unstructured":"5576\u201383."},{"key":"146075","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0245","DOI":"10.1158\/1078-0432.CCR-09-0245"},{"key":"146076","doi-asserted-by":"crossref","unstructured":"Beach C, MacLean D, Majorova D, Arnold JN, Olcina MM. The effects of radiation therapy on the macrophage response in cancer. Front Oncol. 2022;12:1020606.","DOI":"10.3389\/fonc.2022.1020606"},{"key":"146077","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2022.1020606","DOI":"10.3389\/fonc.2022.1020606"},{"key":"146078","doi-asserted-by":"crossref","unstructured":"Raaijmakers K, Adema GJ, Bussink J, Ansems M. Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment. J Exp Clin Cancer Res. 2024;43(1):323.","DOI":"10.1186\/s13046-024-03251-0"},{"key":"146079","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13046-024-03251-0","DOI":"10.1186\/s13046-024-03251-0"},{"key":"146080","unstructured":"Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, et al. The impact of radiation on the tumor microenvironment: effect of dose"},{"key":"146081","unstructured":"and fractionation schedules. Cancer Growth Metastasis. 2018;11:1179064418761639."},{"key":"146082","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1179064418761639","DOI":"10.1177\/1179064418761639"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45030\/53262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45030\/53262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:39:22Z","timestamp":1774273162000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":96,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45030","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}